With a total investment of more than RMB500 million, the hub will focus on the R&D involving diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammatory diseases, rare diseases, multiple sclerosis, and neurology, according to Mr. Jean-Christophe Pointeau, Country Chair of Sanofi China. And it will support the company's global drug R&D by leveraging innovatively cutting-edge biological technologies.

"After the hub having been integrated with Sanofi's current R&D teams in China, the country is expected to be our third pillar in global clinical science and operations, following France and the United States," said Mr. Pointeau.

Mr. Pointeau praised Chengdu for its favorable bio-medical ecosystem, ample talent and education resources, as well as strong government support for the industry. "Chengdu, known as the Land of Abundance, offers a high quality of life to the people here," he said.

By the end of last year, CDHT had seen the presence of 1,541 biological companies, and by far, 6 Nobel laureate-led teams.